ReviewFrontiers in surgery2025
Sentinel lymph node biopsy by transvaginal natural orifice transluminal endoscopic surgery for early-stage endometrial cancer: a systematic literature review.
Review in Frontiers in surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Surgical approach selection and perioperative-pathological characteristics in endometrial cancer: a retrospective observational study.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Sentinel lymph node (SLN) mapping has become a standard approach for early-stage endometrial malignancies, offering reduced morbidity compared to complete lymphadenectomy. Recently, transvaginal natural orifice transluminal endoscopic surgery (vNOTES) has emerged as a novel minimally invasive technique for SLN biopsy, with potential benefits in early surgical outcomes. This systematic review evaluates current evidence on SLN biopsy performed via vNOTES. Material and methods: A systematic literature search was conducted in PubMed, Embase, and Web of Science for articles published between January 1, 2014 and January 31, 2025. Studies were included if they reported SLN biopsy by vNOTES in at least 10 patients with early-stage endometrial cancer and provided detailed data on SLN detection. Our primary outcomes focused on SLN detection and failure rates. Secondary objectives included the early operative outcomes. PROSPERO registration number was CRD42024612607. Results: Seven studies comprising 231 patients were included. The overall bilateral SLN detection rate was 89.2%, with higher detection in the retroperitoneal subgroup (94.3%) compared to the transperitoneal subgroup (81.1%). The overall failure rate was 3.9%. Nodal metastases were reported in 5.6% (10/179) of patients. Intraoperative complications occurred in 4.8% of cases, with bladder injury being the most frequent. The conversion rate to laparoscopy was 6.5%, primarily due to unsuccessful SLN mapping. Postoperative complications occurred in 3% of patients and were mostly minor. Comparisons with conventional laparoscopy showed similar operative times and blood loss, while vNOTES appeared to offer potential advantages in reducing pain and shortening hospital stay. Conclusion: vNOTES is a promising technique for SLN mapping in early-stage endometrial cancer, demonstrating high detection rates with low complication rates. However, evidence remains limited and heterogeneous, highlighting the need for larger, prospective, and randomized studies to validate long-term oncological safety and define its role in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.